Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC  Francesco Gelsomino, MD, Valentina.

Published byPia Fleischer Modified over 5 years ago

Similar presentations

Presentation on theme: "Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC  Francesco Gelsomino, MD, Valentina."— Presentation transcript:

1 Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC  Francesco Gelsomino, MD, Valentina Ambrosini, MD, PhD, Barbara Melotti, MD, Francesca Sperandi, MD, Andrea Ardizzoni, MD  Journal of Thoracic Oncology  Volume 11, Issue 8, Pages e99-e101 (August 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. Multiple focal areas of increased tracer uptake (right and left ilium) without corresponding CT abnormalities show metabolic normalization after treatment and appearance of focal hyperdense lesions on the corresponding CT images. Journal of Thoracic Oncology  , e99-e101DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. A focal area of increased tracer uptake at the lumbar level without corresponding CT abnormalities shows metabolic normalization after treatment and appearance of focal hyperdense lesions on the corresponding CT images. Journal of Thoracic Oncology  , e99-e101DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. An hypermetabolic area at the L3 level showed metabolic normalization at positron emission tomography/CT after treatment, whereas CT revealed an increase in lesion dimensions. Journal of Thoracic Oncology  , e99-e101DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC  Francesco Gelsomino, MD, Valentina."

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC  Ciara Conduit,

Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC  Ciara Conduit,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

Similar presentations

Ads by Google